


MEDICINAL PRODUCTS 2023

INNOSPEC INC. Rank 12 of 48









MEDICINAL PRODUCTS 2023

INNOSPEC INC. Rank 12 of 48



The relative strengths and weaknesses of INNOSPEC INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INNOSPEC INC. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 92% points. The greatest weakness of INNOSPEC INC. is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is 89%, being 94% points above the market average of -5.0%.

| Input Variable | Value in 1000 USD |
|------------------------------------|----------------------|
| Assets, Current | 872,600 |
| Assets, Non-Current | 52,400 |
| General and Administrative Expense | 1,737,700 |
| Goodwill | 403,800 |
| Liabilities, Current | 432,000 |
| Liabilities, Non-Current | 32,800 |
| Other Assets | 54,000 |
| Other Compr. Net Income | -98,300 |
| Other Expenses | 51,600 |
| Other Liabilities | 98,500 |
| Other Net Income | -2,700 |
| Other Revenues | 1,963,700 |
| Property, Plant and Equipment, Net | 220,900 |
| Research and Development | 38,700 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Liabilities | 563,300 |
| Assets | 1,603,700 |
| Expenses | 1,828,000 |
| Revenues | 1,963,700 |
| Stockholders Equity | 1,040,400 |
| Net Income | 133,000 |
| Comprehensive Net Income | 83,850 |
| Economic Capital Ratio | 89% |

